The study is the first clinical-stage adeno-associated virus (AAV) gene therapy study globally for Fabry Disease.
News
Seven new data hubs to be rolled out across UK
The hubs will be the home of “cutting-edge research” for health discoveries.
Keyhole hysterectomy surgery ‘safer and more effective’
The technique removes just part of the uterus using a keyhole surgery.
Final chance to enter into the 2019 Communications Team of the Year & Marketer of the Year!
Entry for the 2019 Communications Team of the Year and Marketer of the Year competitions will be closing for entry on Monday the 16th of September.
Launch of health technology accelerator programme
Just 15 participants were selected for the The Greater Manchester Future of Health Challenge.
Mavenclad real-world data shows sustained efficacy
75% of treated MS patients showed no disability progression at five years post treatment.
Novartis’ Mayzent could preserve mobility in MS patients
The average time to when patients require a wheelchair could be extended from 12 years to 16.3 years.
BMS’ Opdivo shows long-term survival benefit
Opdivo-treated patients continued to experience long-term overall survival benefits compared to docetaxel.
Scotland and Vertex strike CF drug deal
Back in August, the SMC rejected Orkambi and Symkevi following consideration through PACE.
MSEA 2018 winner shares how the finals day has helped to enhance his area of expertise
The 2018 winner of the New Medical Science Liaison of the Year shares his experience with the competition and how it has helped to sharpen his skills.
Parsortix test could avoid unnecessary prostate biopsies
Currently, investigation of symptoms for prostate cancer is typically made via an invasive blood test.
Merck initiates late-stage MS study
The previous Phase II trial met its primary endpoint.
Gilead, Elton John AIDS Foundation launch HIV initiative
The pharma giant announced the “ground-breaking” RADIAN initiative at the Fast-Track Cities 2019 conference in London.
Government injects £130m into cancer & debilitating illnesses
Thousands of NHS patients could receive faster diagnosis and better treatment for life-changing diseases like cancer, dementia and Parkinson’s.
Kymriah leads latest round of SMC decisions
MSD’s Keytruda, Pfizer’s Visimpro, AstraZeneca’s Forxiga and Shionogi’s Senshio were also accepted.
